Changes in characteristics and management among patients with <scp>ST</scp>‐elevation myocardial infarction due to <scp>COVID</scp>‐19 infection

Abstract

The COVID-19 outbreak implies deep changes in the etiopathogenesis and therapeutic management of STEMI patients with COVID-19. The impact on early and long-term outcomes of systemic inflammation and hypercoagulability in this specific population is warranted.